Saturday, February 7, 2026
StockstToday.com Logo
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing
No Result
View All Result
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing
No Result
View All Result
StocksToday.com Logo
No Result
View All Result
Home Breaking News

CytoSorbents Earnings Report Preview March 14 2024

Elaine Mendonca by Elaine Mendonca
March 13, 2024
in Breaking News
0
Mobile app for healthcare
0
SHARES
3
VIEWS
Share on FacebookShare on Twitter

Get ready for CytoSorbents’s upcoming earnings report set to be unveiled on March 14, 2024. Analysts are predicting an EPS of $-0.14 for the company, but investors are hopeful for a positive surprise and optimistic guidance for the next quarter.

In the previous quarter, CytoSorbents missed the EPS estimate by $0.09, causing a slight increase in share price. Reflecting on past performance, here is a breakdown of CytoSorbents’s EPS estimates, actual results, and subsequent price changes in recent quarters:

– Q3 2023: EPS Estimate $-0.12, Actual $-0.21, Price Change 1.0%
– Q2 2023: EPS Estimate $-0.11, Actual $-0.14, Price Change -7.00%
– Q1 2023: EPS Estimate $-0.13, Actual $-0.17, Price Change 16.0%
– Q4 2022: EPS Estimate $-0.17, Actual $-0.01, Price Change 0.0%

With CytoSorbents shares currently trading at $1.0 as of March 12, showing a significant decline over the last year, long-term investors may be feeling uneasy ahead of this earnings announcement.

Stay tuned for more updates on CytoSorbents’s earnings by checking out their calendar on the company’s website.

Cytosorbents Corporation (CTSO) Stock Analysis: March 13, 2024 Update and Price Movement

On March 13, 2024, Cytosorbents Corporation (CTSO) stock opened at $0.99, $0.01 lower than its previous close. Despite opening lower, CTSO shares saw a slight increase of $0.00 since the market last closed, representing a 0.21% rise. This price momentum suggests that there may be some positive sentiment surrounding the stock, even though it is currently trading at the lower end of its range. Investors may be keeping a close eye on CTSO to see if this upward movement continues or if the stock will face resistance at its 200-day moving average. The 52-week range indicates that the stock has been fluctuating within a certain price range over the past year, and trading near the bottom of this range could present a buying opportunity for some investors. It is important for investors to conduct their own research and analysis before making any investment decisions. Keeping track of key indicators like price momentum, moving averages, and trading ranges can help investors make informed decisions about their portfolios. Overall, CTSO’s performance on March 13, 2024, shows some positive movement in the stock price, but investors should continue to monitor the stock closely to see how it performs in the coming days and weeks.

CTSO Stock Performance Declines Significantly in Q3 2024: Revenue, Net Income, and EPS Drop Steeply

On March 13, 2024, CTSO stock experienced a significant decline in its financial performance compared to the previous year and the previous quarter. According to data from CNN Money, the total revenue for CTSO was $34.69 million over the past year, which represented a decrease of 19.64% from the previous year. In the third quarter of the fiscal year, the total revenue was $8.81 million, showing a decrease of 6.47% from the previous quarter.

Similarly, the net income for CTSO was -$32.81 million over the past year, reflecting a decrease of 33.61% from the previous year. In the third quarter, the net income was -$9.19 million, indicating a significant decline of 49.41% from the previous quarter.

The earnings per share (EPS) for CTSO also experienced a decline, with an EPS of -$0.75 over the past year, representing a decrease of 32.94% from the previous year. In the third quarter, the EPS was -$0.21, showing a decrease of 48.21% from the previous quarter.

Tags: CTSO
Elaine Mendonca

Elaine Mendonca

Related Posts

NFT projects
Breaking News

The Impact of TikToks Fate on USChina Relations and American Tech Giants

March 16, 2024
Businesses finance
Breaking News

Blackstone Strategic Credit 2027 Term Fund BGB Announces Monthly Dividend of 93 Cents per Share

March 15, 2024
Healthcare-sector
Breaking News

Analyzing Short Interest in Molina Healthcare Inc MOH

March 15, 2024
Next Post
Biotechnology Stock Market Today (1)

Anticipating Autolus Therapeutics Quarterly Earnings Announcement

Medpace Holdings A Lucrative Investment Opportunity

Finance_Assets (3)

Cantor Fitzgerald Reiterates Overweight Rating and 60 Price Target for Longboard Pharmaceuticals

Recommended

Jakks Pacific Reports Disappointing Q4 2023 Earnings

2 years ago
Ecommerce Stock Exchange

Notable Options Market Activity for Shopify

2 years ago
Fannie Mae Stock

Fannie Mae’s Public Offering Plans Derailed by Prominent Investor

3 months ago
Ocugen Stock

Ocugen Shares Face Critical Test Amid Steep Decline

3 months ago

Categories

  • AI & Quantum Computing
  • Analysis
  • Analyst Ratings
  • Asian Markets
  • Automotive & E-Mobility
  • Banking & Insurance
  • Bitcoin
  • Blockchain
  • Bonds
  • Breaking News
  • Business & Industry Trends
  • Cannabis
  • Chemicals
  • Commodities
  • Consumer & Luxury
  • Crypto Stocks
  • Cryptocurrency
  • Cyber Security
  • DAX
  • Defense & Aerospace
  • Dividends
  • Dow Jones
  • E-Commerce
  • Earnings
  • Emerging Markets
  • Energy & Oil
  • ETF
  • Ethereum & Altcoins
  • European Markets
  • Forex
  • Gaming & Metaverse
  • Gold & Precious Metals
  • Healthcare
  • Hydrogen
  • Index
  • Industrial
  • Insider Trading
  • IPOs
  • Market Commentary
  • Market News
  • MDAX & SDAX
  • Mergers & Acquisitions
  • Nasdaq
  • Newsletter
  • Penny Stocks
  • Pharma & Biotech
  • Real Estate & REITs
  • Renewable Energy
  • S&P 500
  • Semiconductors
  • Space
  • Stock Picks
  • Stock Targets
  • Stocks
  • TecDAX
  • Tech & Software
  • Telecommunications
  • Trading & Momentum
  • Turnaround
  • Uncategorized
  • Value & Growth

Topics

Adobe Alibaba Alphabet Amazon AMD Apple ASML BioNTech Bitcoin Broadcom Coca-Cola Coinbase D-Wave Quantum Eli Lilly Fiserv IBM Intel Kraft Heinz Marvell Technology META Micron Microsoft MP Materials MSCI World ETF Newmont Mining NIO Novo Nordisk Nvidia Ocugen Opendoor Oracle Palantir PayPal Plug Power QuantumScape Robinhood Rocket Lab USA Strategy Super Micro Computer Synopsys Tesla Tilray Unitedhealth Uranium Energy Viking Therapeutics
No Result
View All Result

Highlights

Hydrofarm Holdings: Q4 2025 Earnings Report Date Approaches

Northeast Bancorp Reports Robust Loan Growth Amid Strong Quarterly Performance

Vir Biotechnology’s 2026 Pipeline: A Year of Pivotal Clinical Data

Tellurian Acquisition Finalized as Woodside Takes Control

Coherus BioSciences Forges Key Oncology Alliance with Janssen

TCG BDC Investors Await Key Financial Milestones

Trending

Viking Therapeutics Stock
Earnings

Viking Therapeutics: Upcoming Financial Report to Guide Investor Sentiment

by Rodolfo Hanigan
February 7, 2026
0

Investors in Viking Therapeutics are currently focused on a specific calendar event rather than breaking news. The...

Diginex Stock

Diginex Enters Critical Implementation Phase Following Strategic Moves

February 7, 2026
Deluxe Stock

Deluxe Stock Gains Momentum on Successful Fintech Transition

February 6, 2026
Hydrofarm Holdings Inc Stock

Hydrofarm Holdings: Q4 2025 Earnings Report Date Approaches

February 6, 2026
Northeast Bancorp Stock

Northeast Bancorp Reports Robust Loan Growth Amid Strong Quarterly Performance

February 6, 2026

StocksToday.com is your one-stop destination for the latest stock news and analysis. We provide in-depth coverage of the stock market, including market news, company news, sector news, IPO news, investment strategies, personal finance, international markets, and more.

Follow us on social media:

Recent News

  • Viking Therapeutics: Upcoming Financial Report to Guide Investor Sentiment
  • Diginex Enters Critical Implementation Phase Following Strategic Moves
  • Deluxe Stock Gains Momentum on Successful Fintech Transition

Category

  • About
  • Advertise
  • Careers
  • Contact
  • Imprint
  • Privacy Policy
  • Terms of Service

© 2023 StocksToday.com

No Result
View All Result
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing

© 2023 StocksToday.com